Strong Weekly Performance#
Hims & Hers Health Inc. is on track for its best week ever in terms of stock performance. This surge comes after the company announced a new partnership with Novo Nordisk A/S, which has boosted investor confidence in Hims' weight-loss drug offerings.
Stock Movement#
On Friday, the San Francisco-based telehealth company's shares opened strong, gaining about 2% shortly after 10 AM. This increase adds to a remarkable 51% rise in stock value for the week leading up to Thursday's close. Hims' shares have seen positive movement in three out of the last four trading sessions, reaching their highest point in a month.
Partnership Details#
Earlier this week, Hims revealed its partnership with Novo to sell the weight-loss drugs Ozempic and Wegovy on its platform. This agreement comes after a legal dispute between the two companies, where Novo had filed a lawsuit against Hims. As part of the new deal, Hims will cease advertising compounded versions of Novo's drugs but will continue to sell Ozempic and Wegovy when prescribed by a doctor.
Background of the Dispute#
Novo Nordisk had previously ended its partnership with Hims in June, citing concerns over misleading marketing practices. The Danish pharmaceutical company claimed that Hims was not adequately reducing its advertising of compounded versions of the weight-loss drugs. This led to a decline in Hims' stock as investors worried about the company's future in the weight-loss market and potential legal challenges. The situation worsened early this year when Novo filed a lawsuit against Hims for introducing a copycat version of Wegovy, prompting Hims to remove the product from the market due to regulatory pressures.